Similarly, Th17 cells and IL-17 contribute to carcinogenesis, angiogenesis, and tumor resistance to anti-angiogenic therapy and predict poor prognosis of CRC [44–47]. This evidence concerns the gene IL17A and colorectal carcinoma.